Proteome Sciences plc

OTCPK:PMSN.F Stock Report

Market Cap: US$10.3m

Proteome Sciences Past Earnings Performance

Past criteria checks 0/6

Proteome Sciences's earnings have been declining at an average annual rate of -49.1%, while the Life Sciences industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 7.7% per year.

Key information

-49.1%

Earnings growth rate

-49.1%

EPS growth rate

Life Sciences Industry Growth21.5%
Revenue growth rate7.7%
Return on equityn/a
Net Margin-101.1%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Proteome Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:PMSN.F Revenue, expenses and earnings (GBP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 244-430
31 Mar 245-330
31 Dec 235-230
30 Sep 236-130
30 Jun 238130
31 Mar 238130
31 Dec 228130
30 Sep 227120
30 Jun 226120
31 Mar 226020
31 Dec 215020
30 Sep 215020
30 Jun 215020
31 Mar 215020
31 Dec 205020
30 Sep 205020
30 Jun 205030
31 Mar 205030
31 Dec 195030
30 Sep 194030
30 Jun 193020
31 Mar 193-130
31 Dec 183-130
30 Sep 183-230
30 Jun 183-240
31 Mar 183-240
31 Dec 173-240
30 Sep 173-240
30 Jun 173-240
31 Mar 173-240
31 Dec 163-240
30 Sep 162-340
30 Jun 162-340
31 Mar 162-340
31 Dec 152-340
30 Sep 152-340
30 Jun 152-350
31 Mar 152-350
31 Dec 142-450
30 Sep 142-341
30 Jun 142-332
31 Mar 142-332
31 Dec 132-332

Quality Earnings: PMSN.F is currently unprofitable.

Growing Profit Margin: PMSN.F is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: PMSN.F is unprofitable, and losses have increased over the past 5 years at a rate of 49.1% per year.

Accelerating Growth: Unable to compare PMSN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PMSN.F is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (-4.7%).


Return on Equity

High ROE: PMSN.F's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 23:52
End of Day Share Price 2024/11/27 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Proteome Sciences plc is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullCavendish
Navid MalikCavendish Historical (Cenkos Securities)
Michael Thomas CooperEdison Investment Research